» Articles » PMID: 34566883

CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review

Overview
Specialty Endocrinology
Date 2021 Sep 27
PMID 34566883
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Glycemic variability (GV) appears today as an integral component of glucose homeostasis for the management of type 2 diabetes (T2D). This review aims at investigating the use and relevance of GV parameters in interventional and observational studies for glucose control management in T2D. It will first focus on the relationships between GV parameters measured by continuous glucose monitoring system (CGMS) and glycemic control and T2D-associated complications markers. The second part will be dedicated to the analysis of GV parameters from CGMS as outcomes in interventional studies (pharmacological, nutritional, physical activity) aimed at improving glycemic control in patients with T2D. From 243 articles first identified, 63 articles were included (27 for the first part and 38 for the second part). For both analyses, the majority of the identified studies were pharmacological. Lifestyle studies (including nutritional and physical activity-based studies, N-AP) were poorly represented. Concerning the relationships of GV parameters with those for glycemic control and T2D related-complications, the standard deviation (SD), the coefficient of variation (CV), the mean blood glucose (MBG), and the mean amplitude of the glycemic excursions (MAGEs) were the most studied, showing strong relationships, in particular with HbA1c. Regarding the use and relevance of GV as an outcome in interventional studies, in pharmacological ones, SD, MAGE, MBG, and time in range (TIR) were the GV parameters used as main criteria in most studies, showing significant improvement after intervention, in parallel or not with glycemic control parameters' (HbA1c, FBG, and PPBG) improvement. In N-AP studies, the same results were observed for SD, MAGE, and TIR. Despite the small number of N-AP studies addressing both GV and glycemic control parameters compared to pharmacological ones, N-AP studies have shown promising results on GV parameters and would require more in-depth work. Evaluating CGMS-GV parameters as outcomes in interventional studies may provide a more integrative dimension of glucose control than the standard postprandial follow-up. GV appears to be a key component of T2D dysglycemia, and some parameters such as MAGE, SD, or TIR could be used routinely in addition to classical markers of glycemic control such as HbA1c, fasting, or postprandial glycemia.

Citing Articles

Continuous Glucose Monitors and Programmed Shared Medical Appointments in Managing Type 2 Diabetes Mellitus Among First Nation Women in Australia: A Co-Designed Feasibility Study.

Stevens J, Firth W, Dooley L, Longbottom H, Wills K, Egger G Am J Lifestyle Med. 2025; 15598276241312084.

PMID: 39802907 PMC: 11713975. DOI: 10.1177/15598276241312084.


Incidence and influencing factors for hypoglycemia in maintenance hemodialysis patients with diabetic kidney disease: a meta-analysis.

Jiang F, Wu B, Qin Z, Xie Y, Yi N, Chen W Am J Transl Res. 2024; 16(10):5216-5227.

PMID: 39544810 PMC: 11558428. DOI: 10.62347/ESHE6987.


Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes Mellitus: The SIDAXA Study.

Chawla M, Panneerselvam D, Gundgurthy A, Sud S, Alamchandani R, Aneja P Cureus. 2024; 16(5):e60815.

PMID: 38910691 PMC: 11191412. DOI: 10.7759/cureus.60815.


The impact of slowly digestible and resistant starch on glucose homeostasis and insulin resistance.

Chisbert M, Castell A, Vinoy S, Nazare J Curr Opin Clin Nutr Metab Care. 2024; 27(4):338-343.

PMID: 38836807 PMC: 11155281. DOI: 10.1097/MCO.0000000000001044.


Enhancement of Ambulatory Glucose Profile for Decision Assistance and Treatment Adjustments.

Satuluri V, Ponnusamy V Diagnostics (Basel). 2024; 14(4).

PMID: 38396474 PMC: 10888350. DOI: 10.3390/diagnostics14040436.


References
1.
Li L, Yao M, Ma J, Xue P, Li Y . Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system. Endocr J. 2019; 66(10):871-880. DOI: 10.1507/endocrj.EJ19-0016. View

2.
Kim H, Shin J, Lee S, Kim E, Cho J, Son H . A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther. 2013; 15(10):810-6. DOI: 10.1089/dia.2013.0038. View

3.
Nomoto H, Miyoshi H, Sugawara H, Ono K, Yanagiya S, Oita M . A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. Diabetol Metab Syndr. 2017; 9:54. PMC: 5514514. DOI: 10.1186/s13098-017-0255-8. View

4.
Siegelaar S, Barwari T, Kulik W, Hoekstra J, DeVries J . No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol. 2011; 5(1):86-92. PMC: 3045241. DOI: 10.1177/193229681100500112. View

5.
Manski-Nankervis J, Yates C, Blackberry I, Furler J, Ginnivan L, Cohen N . Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study. Diabet Med. 2015; 33(6):803-11. DOI: 10.1111/dme.12979. View